RecruitingPhase 2NCT07300449
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
Studying Hepatoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Principal Investigator
- Junting HuangSunYat Sen University Cancer Center
- Intervention
- Very low-risk group(drug)
- Enrollment
- 100 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (1)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07300449 on ClinicalTrials.govOther trials for Hepatoblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07188311Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenSun Yat-sen University
- RECRUITINGNCT05556642Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium InitiativeChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE1, PHASE2NCT04634357ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular CarcinomaEureka Therapeutics Inc.
- RECRUITINGPHASE1, PHASE2NCT04901702Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT04478292A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyShanghai Children's Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT03017326Paediatric Hepatic International Tumour TrialUniversity of Birmingham
- ACTIVE NOT RECRUITINGPHASE3NCT00980460Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver CancerNational Cancer Institute (NCI)